Gelnique Approved for Overactive Bladder

powered by healthline

Average Ratings

A topical gel for treating symptoms

WEDNESDAY, Jan. 28 (HealthDay News) -- The U.S. Food and Drug Administration has approved Watson Pharmaceuticals' Gelnique (oxybutynin chloride) to treat symptoms of overactive bladder, the company said in a news release.

Gelnique is a topical gel that's applied daily to the thigh, abdomen, upper arm or shoulder. Since it's absorbed through the skin, it's not metabolized by the liver as it would be were the drug's active ingredient, oxybutynin, taken orally, Watson said.

The most frequent side effects reported during clinical testing included dry mouth and reactions where the gel was applied.

Overactive bladder, with symptoms including incontinence, urgency and waking up at night to urinate, affects as many as 33 million adults in the United States, the company said.

More information

The U.S. National Institute on Aging has more on urinary incontinence.


-- Scott Roberts
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools